# A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct06954961/  
OnCo record `nct06954961` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing D-0502 in HR-positive / HER2-negative breast cancer, now recruiting.

## Summary

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06954961, led by InventisBio, and recruiting on the registry. Official title: A Randomised, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. Planned enrolment is 640 participants (estimated). The study started in 2022-09-15 and primary completion is expected in 2026-11-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06954961
- Phase: 3
- Setting: A Randomized, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Sponsor: InventisBio
- Enrolled: 640

## Sources

- ClinicalTrials.gov NCT06954961: https://clinicaltrials.gov/study/NCT06954961

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [D-0502](https://onco.cc/drugs/d-0502/)
- companies: [InventisBio](https://onco.cc/companies/inventisbio/)

---
JSON: https://onco.cc/api/v1/entities/nct06954961.json